Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-resistant Recurrent Ovarian Cancer 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 15Paclitaxel 13Hyperthermic Intraperitoneal Chemotherapy 6Cisplatin 5olaparib 4niraparib 4Bevacizumab 4oregovomab 3Topotecan 3Immunohistochemistry 3Gemcitabine 3Drug Therapy 3Docetaxel 3Cyclophosphamide 3Chemotherapy, Adjuvant 3Amplified Fragment Length Polymorphism Analysis 3pembrolizumab 2liposomal doxorubicin 2anlotinib 2ST 1481 2Radiotherapy 2Polymerase Chain Reaction 2Oxaliplatin 2Neoadjuvant Therapy 2Gene Expression Profiling 2Fluorouracil 2Flow Cytometry 2Diathermy 2Cytoreduction Surgical Procedures 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Ovarian Epithelial × 1-dodecylpyridoxal × Clear all
NCT04983550 2021-07-30

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
126 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡